Iovance Biotherapeutics Inc (NASDAQ: IOVA) Loses -3.49% From High. Why That Could Change?

Currently, there are 255.92M common shares owned by the public and among those 199.70M shares have been available to trade.

However, the script later moved the day high at 9.98, up 8.39%. The company’s stock has a 5-day price change of 25.63% and 151.90% over the past three months. IOVA shares are trading 22.39% year to date (YTD), with the 12-month market performance up to 34.10% higher. It has a 12-month low price of $3.21 and touched a high of $10.31 over the same period. IOVA has an average intraday trading volume of 1.08 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 23.05%, 27.53%, and 50.17% respectively.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 72.83% of the company’s 255.92M shares outstanding.

It has a market capitalization of $2.55B and a beta (3y monthly) value of 0.40. The earnings-per-share (ttm) stands at -$2.08. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.77% over the week and 7.36% over the month.

Analysts forecast that Iovance Biotherapeutics Inc (IOVA) will achieve an EPS of $Sunnova Energy International In for the current quarter, $12.15 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Innoviva, Inc. while analysts give the company a high EPS estimate of $Inventiva S.A. – American Depos. Comparatively, EPS for the current quarter was $IOVANCE BIOTHERAP.DL-,001 a year ago. Earnings per share for the fiscal year are expected to increase by 24.90%, and 27.89% over the next financial year.

Looking at the support for the IOVA, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 20, 2023, with the firm’s price target at $12.

Most Popular

Related Posts